



1648/122

PATENT  
ATTORNEY DOCKET NO. 50026/061001

Certificate of Mailing: Date of Deposit: April 12, 2007

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Megan Kiley  
Printed name of person mailing correspondence

Megan Kiley  
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Inoue et al.	Confirmation No.:	7683
Serial No.:	10/587,123	Art Unit:	1645
371(c) Date:	January 18, 2007	Examiner:	Not Yet Assigned
Customer No.:	21559		
Title:	METHOD FOR PRODUCING VIRAL VECTORS		

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents, U.S. patent application publications, and U.S. patent applications.

Applicants note that AU 200046146 A, CN 1355851 A, EP 1186667 A1, and KR 2002014786 A, are patent family members of WO 00/70070 A1, submitted to the USPTO with the IDS filed on February 14, 2007. Accordingly, copies are not enclosed.

In addition, Applicants list CN 1357044 A on the enclosed Form PTO-1449. CN

1357044 A is cumulative of the WO 00/70055 publication submitted to the USPTO with the IDS filed on February 14, 2007. Accordingly, a copy of CN 1357044 A is not enclosed.

Applicants also note that AU 7335196 A, CA 2236113 A1, CN 1207123 A, B, EP 1325960 A2, and HK 1018287 A1, are patent family members of WO 97/16538 A1 a copy of which is submitted herewith, and copies of the family members are not enclosed.

The enclosed copies of JP 7-509616 A1, JP 10-506542 A1, WO 97/16538 A1, WO 03/092738 A1, WO 03/102183 A1, WO 04/038029, and Hatanaka, M., ed., Uirusugaku, Asakura Shoten, pp. 247-248 (1997), are written in the Japanese language. An English language translation for each of these references is enclosed, with the exception of JP 7-509616 A1, where only an English translation of the claims is enclosed.

Furthermore, WO 97/16171, WO 00/09700 A1, are written in the Japanese language, and WO 00/27430 A2, A3 is written in the German language. In accordance with 37 C.F.R. § 1.98, English language abstracts are provided for these documents.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.


This statement is being filed before the receipt of a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account

No. 03-2095.

Respectfully submitted,

Date: 12 April 2007

  
James D. DeCamp, Ph.D.  
Reg. No. 43,580

JAN N. TITEL, Ph.D.  
Reg. No. 52,290

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045



Sheet 1 of 9

SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	50026/061001
	Serial No.	10/587,123
	Applicant	Inoue et al.
	371 (c) Date	January 18, 2007
	Group	1645
	IDS Filed	April 12, 2007

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	10/562,408		You et al.			Dec. 23, 2005
	10/578,085		Okano et al.			May 3, 2006
	2002/0002143 A1	Jan. 03, 2002	Kano et al.			
	2002/0081706 A1	Jun. 27, 2002	Nagai et al.			
	2002/0098576 A1	Jul. 25, 2002	Nagai et al.			
	2002/0100066 A1	Jul. 25, 2002	Nagai et al.			
	2003/0170210 A1	Sep. 11, 2003	Masaki et al.			
	2003/0170897 A1	Sep. 11, 2003	Imai et al.			
	2003/0203489 A1	Oct. 30, 2003	Yonemitsu et al.			
	2004/0005296 A1	Jan. 8, 2004	Yonemitsu et al.			
	2004/0053877 A1	Mar. 18, 2004	Fukumura et al.			
	2004/0101965 A1	May 27, 2004	Griesenbach et al.			
	2004/0121308 A1	Jun. 24, 2004	Nagai et al.			
	2005/0130123 A1	Jun. 16, 2005	Inoue et al.			
	2005/0221292 A1	Oct. 6, 2005	Kinoh et al.			
	2006/0104950 A1	May 18, 2006	Okano et al.			
	2006/0216824 A1	Sep. 28, 2006	Tokusumi et al.			
	2007/0009949 A1	Jan. 11, 2007	Kitazato et al.			
	5,962,274	Oct. 5, 1999	Parks			
	6,040,174	Mar. 21, 2000	Imler et al.			
	6,746,860	Jun. 8, 2004	Tokusumi et al.			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	50026/061001
	Serial No.	10/587,123
	Applicant	Inoue et al.
	371 (c) Date	January 18, 2007
	Group	1645
	IDS Filed	April 12, 2007

	6,828,138	Dec. 7, 2004	Nagai et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	AU 7335196 A	May 22, 1997	Australia			
	AU 200046146 A	Dec. 5, 2000	Australia /			
	CA 2236113 A1	May 9, 1997	Canada			
	CN 1207123 A, B	Feb. 3, 1999	China			No
	CN 1357044 A	Jul. 3, 2002	China			No
	CN 1355851 A	Jun. 26, 2002	China			No
	EP 0863202 A1	Sep. 9, 1998	EPO			
	EP 1106692 A1	Jun. 13, 2001	EPO			
	EP 1179594 A1	Feb. 13, 2002	EPO			
	EP 1186667 A1	Mar. 13, 2002	EPO			
	EP 1325960 A2	Jul. 9, 2003	EPO			
	HK 1018287 A1	Nov. 21, 2003	Hong Kong			
	JP 7-509616 A1	Oct. 26, 1995	Japan			Claims only
	JP 10-506542 A1	Jun. 30, 1998	Japan			Yes
	KR 2002014786 A	Feb. 25, 2002	Korea			
	WO 97/16171 A1	May 9, 1997	WIPO			English Abstract
	WO 97/16538 A1	May 9, 1997	WIPO			Yes
	WO 00/09700 A1	Feb. 24, 2000	WIPO			English Abstract
	WO 00/27430 A2, A3	May 18, 2000	WIPO			English Abstract

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	50026/061001
	Serial No.	10/587,123
	Applicant	Inoue et al.
	371 (c) Date	January 18, 2007
	Group	1645
	IDS Filed	April 12, 2007

	WO 01/32898 A2, A3	May 10, 2001	WIPO			
	WO 03/092738 A1	Nov. 13, 2003	WIPO			Yes
	WO 03/102183 A1	Dec. 11, 2003	WIPO			Yes
	WO 04/038029 A1	May 6, 2004	WIPO			Yes
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Ali and Nayak, "Assembly of Sendai Virus: M Protein Interacts with F and HN Proteins and with the Cytoplasmic Tail and Transmembrane Domain of F Protein," <i>Virology</i> , 276(2):289-303 (2000).					
	Altenschmidt et al., "Specific Cytotoxic T Lymphocytes In Gene Therapy," <i>J. Mol. Med.</i> 75(4):259-266 (1997).					
	Arai et al., "A New System For Stringent, High-Titer Vesicular Stomatitis Virus G Protein-Pseudotyped Retrovirus Vector Induction by Introduction of Cre Recombinase into Stable Prepackaging Cell Lines," <i>J. Virol.</i> 72(2):1115-1121 (1998).					
	Auten et al., "Effect of Scaffold Attachment Region on Transgene Expression in Retrovirus Vector-Transduced Primary T Cells and Macrophages," <i>Hum. Gene Ther.</i> 10(8):1389-1399 (1999).					
	Ayuk et al., "Establishment of an Optimised Gene Transfer Protocol for Human Primary T Lymphocytes According to Clinical Requirements," <i>Gene Ther.</i> 6(10):1788-1792 (1999).					
	Bagai et al., "Hemagglutinin-Neuraminidase Enhances F Protein-Mediated Membrane Fusion of Reconstituted Sendai Virus Envelopes with Cells," <i>J. Virol.</i> 67(6):3312-3318 (1993).					
	Barclay and Palese, "Influenza B Viruses with Site-Specific Mutations Introduced into the HA Gene," <i>J. Virol.</i> 69(2):1275-1279 (1995).					
	Bergemann et al., "Excision of Specific DNA-Sequences From Integrated Retroviral Vectors Via Site-Specific Recombination," <i>Nucleic Acids Res.</i> 23(21):4451-4456 (1995).					
	Bitzer et al., "Sendai Virus Efficiently Infects Cells via the Asialoglycoprotein Receptor and Requires the Presence of Cleaved F <sub>0</sub> Precursor Proteins for this Alternative Route of Cell Entry," <i>J. Virol.</i> 71(7):5481-5486 (1997).					
	Blaese et al., "T Lymphocyte-Directed Gene Therapy for ADA <sup>-</sup> SCID: Initial Trial Results After 4 Years," <i>Science</i> 270(5235):475-480 (1995).					
	Brenner, "Gene Transfer to Hematopoietic Cells," <i>N. Eng. J. Med.</i> 335(5):337-339 (1996).					
	Brown and Rose, "Sorting of GPI-Anchored Proteins to Glycolipid-Enriched Membrane Subdomains during Transport to the Apical Cell Surface," <i>Cell</i> 68(3):533-544 (1992).					
	Buchsacher and Wong-Staal, "Development of Lentiviral Vectors for Gene Therapy for Human Diseases," <i>Blood</i> 95(8):2499-2504 (2000).					


EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50026/061001
		Serial No.	10/587,123
		Applicant	Inoue et al.
		371 (c) Date	January 18, 2007
		Group	1645
		IDS Filed	April 12, 2007
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

	Bunnell et al., "Efficient In Vivo Marking of Primary CD4+ T Lymphocytes in Nonhuman Primates Using a Gibbon Ape Leukemia Virus-Derived Retroviral Vector," <i>Blood</i> 89(6):1987-1995 (1997).
	Caravokyri et al., "Defective Synthesis of Envelope Proteins by Temperature-Sensitive Mutants Representing Complementation Groups B and D of Respiratory Syncytial Virus," <i>J. Gen. Virol.</i> 72(Pt. 10):2501-2508 (1991).
	Cathomen et al., "A Matrix-Less Measles Virus Is Infectious and Elicits Extensive Cell Fusion: Consequences for Propagation in the Brain," <i>EMBO J.</i> 17(14):3899-3908 (1998).
	Cathomen et al., "Measles Viruses with Altered Envelope Protein Cytoplasmic Tails Gain Cell Fusion Competence," <i>J. Virol.</i> 72(2):1224-1234 (1998).
	Chen et al., "A Unique Substrate Recognition Profile for Matrix Metalloproteinase-2," <i>J. Biol. Chem.</i> 277(6):4485-4491 (2002).
	Conzelmann, "Nonsegmented Negative-Strand RNA Viruses: Genetics and Manipulation of Viral Genomes," <i>Annu. Rev. Genet.</i> , 32:123-162 (1998).
	Costello et al., "Gene Transfer into Stimulated and Unstimulated T Lymphocytes by HIV-1-Derived Lentiviral Vectors," <i>Gene Ther.</i> 7(7):596-604 (2000).
	Dardalhon et al., "Lentivirus-mediated Gene Transfer in Primary T Cells Is Enhanced by a Central DNA Flap," <i>Gene Ther.</i> 8(3):190-198 (2001).
	Di Nicola et al., "Recombinant Adenoviral Vector-LipofectAMINE Complex for Gene Transduction into Human T Lymphocytes," <i>Hum. Gene Ther.</i> 10(11):1875-1884 (1999).
	Douglas et al., "Targeted Gene Delivery by Tropism-Modified Adenoviral Vectors," <i>Nature Biotechnol.</i> 14(11):1574-1578 (1996).
	Friedman, "Expression of Human Adenosine Deaminase Using a Transmissible Murine Retrovirus Vector System," <i>Proc. Natl. Acad. Sci. USA</i> 82(3):703-707 (1985).
	Garoff et al., "Virus Maturation by Budding," <i>Microbiol. Mol. Biol. Rev.</i> 62(4):1171-1190 (1998).
	Ghivizzani et al., "Direct Retrovirus-Mediated Gene Transfer to the Synovium of the Rabbit Knee: Implications for Arthritis Gene Therapy," <i>Gene Ther.</i> 4(9):977-982 (1997).
	Gitman et al., "Use of Virus-Attached Antibodies or Insulin Molecules to Mediate Fusion Between Sendai Virus Envelopes and Neuraminidase-Treated Cells," <i>Biochemistry</i> 24(11):2762-2768 (1985).
	Gladow et al., "MLV-10A1 Retrovirus Pseudotype Efficiently Transduces Primary Human CD4 <sup>+</sup> T Lymphocytes," <i>J. Gene Med.</i> 2(6):409-415 (2000).
	Gómez-Puertas et al., "Influenza Virus Matrix Protein Is the Major Driving Force in Virus Budding," <i>J. Virol.</i> 74(24):11538-11547 (2000).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50026/061001
		Serial No.	10/587,123
		Applicant	Inoue et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		371 (c) Date	January 18, 2007
		Group	1645
		IDS Filed	April 12, 2007
(37 C.F.R. § 1.98(b))			

	Gould, "Comparison of the Deduced Matrix and Fusion Protein Sequences of Equine Morbillivirus with Cognate Genes of the Paramyxoviridae," <i>Virus Res.</i> 43(1):17-31 (1996).
	Harcourt et al., "Molecular Characterization of Nipah Virus, a Newly Emergent Paramyxovirus," <i>Virology</i> 271(2):334-349 (2000).
	Hasan et al., "Creation of an Infectious Recombinant Sendai Virus Expressing the Firefly Luciferase Gene from the 3' Proximal First Locus," <i>J. Gen. Virol.</i> 78(Pt 11):2813-2820 (1997).
	Hatanaka, M., ed., <i>Uirusugaku, Asakura Shoten</i> , pp. 247-248 (1997) (with English language translation).
	Hege and Roberts, "T-Cell Gene Therapy," <i>Curr. Opin. Biotechnol.</i> 7(6):629-634 (1996).
	Heggeness et al., "In Vitro Assembly of the Nonglycosylated Membrane Protein (M) of Sendai Virus," <i>Proc. Natl. Acad. Sci. USA</i> 79(20):6232-6236 (1982).
	Huntley et al., "Phosphorylation of Sendai Virus Phosphoprotein by Cellular Protein Kinase C $\zeta$ ," <i>J. Biol. Chem.</i> 272(26):16578-16584 (1997).
	Ikeda et al., "Recombinant Sendai Virus-Mediated Gene Transfer into Adult Rat Retinal Tissue: Efficient Gene Transfer by Brief Exposure," <i>Exp. Eye Res.</i> 75(1):39-48 (2002).
	Imbert et al., "Highly Efficient Retroviral Gene Transfer into Human Primary T Lymphocytes Derived from Peripheral Blood," <i>Cancer Gene Ther.</i> 1(4):259-265 (1994).
	Johnson et al., "Metalloproteinase Cleavable Linkers Can Target the Cytotoxicity of Fusogenic Membrane Glycoproteins in Gliomas," <i>Abstracts from the Fourth Annual Meeting of the American Society of Gene Therapy: Mol. Ther.</i> 3(5):S25(63) (2001).
	Karron et al., "Respiratory Syncytial Virus (RSV) SH and G Proteins Are Not Essential for Viral Replication <i>In Vitro</i> : Clinical Evaluation and Molecular Characterization of a Cold-Passaged, Attenuated RSV Subgroup B Mutant," <i>Proc. Natl. Acad. Sci. USA</i> 94(25): 13961-13966 (1997).
	Kato et al., "Initiation of Sendai Virus Multiplication from Transfected cDNA or RNA with Negative or Positive Sense," <i>Genes Cells</i> 1(6):569-579 (1996).
	Kido et al., "The Human Mucus Protease Inhibitor and its Mutants Are Novel Defensive Compounds against Infection with Influenza A and Sendai Viruses," <i>Biopolymers</i> 51(1):79-86 (1999).
	Kondo et al., "Temperature-Sensitive Phenotype of a Mutant Sendai Virus Strain Is Caused by its Insufficient Accumulation of the M Protein," <i>J. Biol. Chem.</i> 268(29):21924-21930 (1993).
	Kridel et al., "Substrate Hydrolysis by Matrix Metalloproteinase-9," <i>J. Biol. Chem.</i> 276(23):20572-20578 (2001).
	Kühlcke et al., "Highly Efficient Retroviral Gene Transfer Based on Centrifugation-Mediated Vector Preloading of Tissue Culture Vessels," <i>Mol. Ther.</i> 5(4):473-478 (2002).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



Sheet 6 of 9

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50026/061001
		Serial No.	10/587,123
		Applicant	Inoue et al.
		371 (c) Date	January 18, 2007
		Group	1645
		IDS Filed	April 12, 2007
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

	Leyrer et al., "Sendai Virus-Like Particles Devoid of Haemagglutinin-Neuraminidase Protein Infect Cells Via the Human Asialoglycoprotein Receptor," <i>J. Gen. Virol.</i> 79(Pt. 4):683-687 (1998).
	Li et al., "Effect of Cleavage Mutants on Syncytium Formation Directed by the Wild-Type Fusion Protein of Newcastle Disease Virus," <i>J. Virol.</i> 72(5):3789-3795 (1998).
	Lin et al., "The RNA Binding Region of the Paramyxovirus SV5 V and P Proteins," <i>Virology</i> 238(2):460-469 (1997).
	Manié et al., "Measles Virus Structural Components Are Enriched into Lipid Raft Microdomains: A Potential Cellular Location for Virus Assembly," <i>J. Virol.</i> 74(1):305-311 (2000).
	Markwell et al., "An Alternative Route of Infection for Viruses: Entry by Means of the Asialoglycoprotein Receptor of a Sendai Virus Mutant Lacking its Attachment Protein," <i>Proc. Natl. Acad. Sci. USA</i> 82(4):978-982 (1985).
	Martin et al., "Retrovirus Targeting by Tropism Restriction to Melanoma Cells," <i>J. Virol.</i> 73(8):6923-6929 (1999).
	Matsumura et al., "RNA Editing-Like Phenomenon in Paramyxovirus V Gene mRNA Observed in Insect Cells Infected With a Recombinant Baculovirus," <i>J. Gen. Virol.</i> 80(Pt. 1):117-123 (1999).
	Mebatsion et al., "Budding of Rabies Virus Particles in the Absence of the Spike Glycoprotein," <i>Cell</i> 84(6):941-951 (1996).
	Mebatsion et al., "Matrix Protein of Rabies Virus Is Responsible for the Assembly and Budding of Bullet-Shaped Particles and Interacts with the Transmembrane Spike Glycoprotein G," <i>J. Virol.</i> 73(1):242-250 (1999).
	Misaki et al., "Gene-Transferred Oligodonal T Cells Predominantly Persist in Peripheral Blood From an Adenosine Deaminase-Deficient Patient During Gene Therapy," <i>Mol. Ther.</i> 3(1):24-27 (2001).
	Miura et al., "HVJ (Sendai Virus)-Induced Envelope Fusion and Cell Fusion Are Blocked by Monoclonal Anti-HN Protein Antibody That Does Not Inhibit Hemagglutination Activity of HVJ," <i>Exp. Cell Res.</i> 141(2):409-420 (1982).
	Morikawa et al., "Characterization of Temperature-Sensitive Mutants of Measles Virus," <i>Kitasato Arch. Exp. Med.</i> 64(1):15-30 (1991).
	Mottet et al., "Characterization of Sendai Virus M Protein Mutants that Can Partially Interfere with Virus Particle Production," <i>J. Gen. Virol.</i> 80(Pt. 11):2977-2986 (1999).
	Mottet et al., "A Sendai Virus Vector Leading to the Efficient Expression of Mutant M Proteins Interfering with Virus Particle Budding," <i>Virology</i> 221(1):159-171 (1996).
	Movassagh et al., "Retrovirus-Mediated Gene Transfer into T Cells: 95% Transduction Efficiency Without Further In Vitro Selection," <i>Hum. Gene Ther.</i> 11(8):1189-1200 (2000).
	Nagai, "Paramyxovirus Replication and Pathogenesis. Reverse Genetics Transforms Understanding," <i>Rev. Med. Virol.</i> 9(2):83-99 (1999).
	Nieuwenhuizen et al., "Fluorogenic Peptide Amide Substrates for the Estimation of Plasminogen Activators and Plasmin," <i>Anal. Biochem.</i> 83(1):143-148 (1977).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	50026/061001
	Serial No.	10/587,123
	Applicant	Inoue et al.
	371 (c) Date	January 18, 2007
	Group	1645
	IDS Filed	April 12, 2007

	Okano et al., "Recombinant Sendai Virus Vectors for Activated T Lymphocytes," <i>Gene Ther.</i> 10(16):1381-1391 (2003).
	Peng et al., "Selective Transduction of Protease-Rich Tumors by Matrix-Metalloproteinase-Targeted Retroviral Vectors," <i>Gene Ther.</i> 6(9):1552-1557 (1999).
	Pollok et al., "High-Efficiency Gene Transfer into Normal and Adenosine Deaminase-Deficient T Lymphocytes is Mediated by Transduction on Recombinant Fibronectin Fragments," <i>J. Virol.</i> 72(6):4882-4892 (1998).
	Ponimaskin et al., "Sendai Virosomes Revisited: Reconstitution with Exogenous Lipids Leads to Potent Vehicles for Gene Transfer," <i>Virology</i> 269(2):391-403 (2000).
	Puls and Minchin, "Gene Transfer and Expression of a Non-Viral Polycation-Based Vector in CD4 <sup>+</sup> Cells," <i>Gene Ther.</i> 6(10):1774-1778 (1999).
	Ramani et al., "Novel Gene Delivery to Liver Cells Using Engineered Virosomes," <i>FEBS Lett.</i> 404(2-3):164-168 (1997).
	Rosenberg et al., "Gene Transfer Into Humans—Immunotherapy of Patients with Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene Transduction," <i>N. Eng. J. Med.</i> 323(9):570-578 (1990).
	Rudoll et al., "High-Efficiency Retroviral Vector Mediated Gene Transfer into Human Peripheral Blood CD4 <sup>+</sup> T Lymphocytes," <i>Gene Ther.</i> 3(8):695-705 (1996).
	Sakai et al., "Accommodation of Foreign Genes into the Sendai Virus Genome: Sizes of Inserted Genes and Viral Replication," <i>FEBS Lett.</i> 456(2):221-226 (1999).
	Sanderson et al., "Sendai Virus Assembly: M Protein Binds to Viral Glycoproteins in Transit through the Secretory Pathway," <i>J. Virol.</i> 67(2):651-663 (1993).
	Sanderson et al., "Sendai Virus M Protein Binds Independently to either the F or the HN Glycoprotein In Vivo," <i>J. Virol.</i> 68(1):69-76 (1994).
	Schwartz et al., "Synthetic DNA-Compacting Peptides Derived from Human Sequence Enhance Cationic Lipid-Mediated Gene Transfer <i>In Vitro</i> and <i>In Vivo</i> ," <i>Gene Ther.</i> 6(2):282-292 (1999).
	Shiotani et al. "Skeletal Muscle Regeneration After Insulin-Like Growth Factor I Gene Transfer by Recombinant Sendai Virus Vector," <i>Gene Ther.</i> 8(14):1043-1050 (2001).
	Simons and Ikonen, "Functional Rafts in Cell Membranes," <i>Nature</i> 387(6633):569-572 (1997).
	Spiegel et al., "Pseudotype Formation of Moloney Murine Leukemia Virus with Sendai Virus Glycoprotein F," <i>J. Virol.</i> 72(6):5296-5302 (1998).
	Spielhofer et al., "Chimeric Measles Viruses with a Foreign Envelope," <i>J. Virol.</i> 72(3):2150-2159 (1998).


EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	50026/061001
	Serial No.	10/587,123
	Applicant	Inoue et al.
	371 (c) Date	January 18, 2007
	Group	1645
	IDS Filed	April 12, 2007

	Stockschl�der et al., "Expansion and Fibronectin-Enhanced Retroviral Transduction of Primary Human T Lymphocytes for Adoptive Immunotherapy," <i>J. Hematother. Stem Cell Res.</i> 8(4):401-410 (1999).
	Stone-Hulslander and Morrison, "Detection of an Interaction Between the HN and F Proteins in Newcastle Disease Virus-Infected Cells," <i>J. Virol.</i> 71(9):6287-6295 (1997).
	Stricker et al., "The Sendai Virus Matrix Protein Appears to be Recruited in the Cytoplasm by the Viral Nucleocapsid to Function in Viral Assembly and Budding," <i>J. Gen. Virol.</i> 75(Pt. 5):1031-1042 (1994).
	Stricker and Roux, "The Major Glycoprotein of Sendai Virus Is Dispensable for Efficient Virus Particle Budding," <i>J. Gen. Virol.</i> 72(Pt. 7):1703-1707 (1991).
	Taira et al., "Transfection of Sendai Virus F Gene cDNA with Mutations at Its Cleavage Site and HN Gene cDNA into COS Cells Induces Cell Fusion," <i>Arch. Virol.</i> 140(1):187-194 (1995).
	Takimoto et al., "Role of Matrix and Fusion Proteins in Budding of Sendai Virus," <i>J. Virol.</i> 75(23):11384-11391 (2001).
	Tanabayashi et al., "Effect on Fusion Induction of Point Mutations Introduced into the F Protein of Mumps Virus," <i>Virology</i> 204(2):851-853 (1994).
	Tashiro et al., "Changes in Specific Cleavability of the Sendai Virus Fusion Protein: Implications for Pathogenicity in Mice," <i>J. Gen. Virol.</i> 73(Pt. 6):1575-1579 (1992).
	Thompson and Portner, "Localization of Functional Sites on the Hemagglutinin-Neuraminidase Glycoprotein of Sendai Virus by Sequence Analysis of Antigenic and Temperature-Sensitive Mutants," <i>Virology</i> 160(1):1-8 (1987).
	Tomasi et al., "Conjugation of Specific Antibodies to Sendai Virus Particles," <i>FEBS Lett.</i> 143(2):252-256 (1982).
	Tuffereau et al., "The Role of Haemagglutinin-Neuraminidase Glycoprotein Cell Surface Expression in the Survival of Sendai Virus-Infected BHK-21 Cells," <i>J. Gen. Virol.</i> 66(Pt. 11):2313-2318 (1985).
	Tuohy and Mathisen, "T Cell Design for Therapy in Autoimmune Demyelinating Disease," <i>J. Neuroimmunol.</i> 107(2): 226-232 (2000).
	Turk et al., "Determination of Protease Cleavage Site Motifs Using Mixture-Based Oriented Peptide Libraries," <i>Nature Biotechnol.</i> 19(7):661-667 (2001).
	Uchida et al., "High Efficiency Gene Transfer into Murine T Cell Clones Using a Retroviral Vector," <i>J. Immunol.</i> 136(5):1876-1879 (1986).
	Wickham et al., "Targeted Adenovirus-Mediated Gene Delivery to T Cells Via CD3," <i>J. Virol.</i> 71(10):7663-7669 (1997).
	Yao et al., "Differences in the Role of the Cytoplasmic Domain of Human Parainfluenza Virus Fusion Proteins," <i>J. Virol.</i> 69(11):7045-7053 (1995).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

Sheet 9 of 9

SUBSTITUTE FORM PTO-1449 (REV. 11-2003) DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	50026/061001
	Serial No.	10/587,123
	Applicant	Inoue et al.
	371 (c) Date	January 18, 2007
	Group	1645
	IDS Filed	April 12, 2007

	Yonemitsu et al., "Efficient Gene Transfer to Airway Epithelium Using Recombinant Sendai Virus," <i>Nature Biotechnol.</i> 18(9):970-973 (2000).
	Yoshida et al., "Membrane (M) Protein of HVJ (Sendai Virus): Its Role in Virus Assembly," <i>Virology</i> 71(1):143-161 (1976).
	Yoshida et al., "Studies on the Role of M Protein in Virus Assembly Using a ts Mutant of HVJ (Sendai Virus)," <i>Virology</i> 92(1):139-154 (1979).
	Yu et al., "Sendai Virus-Based Expression of HIV-1 gp120: Reinforcement by the V(-) Version," <i>Genes to Cells</i> 2(7):457-466 (1997).
	Zhirnov et al., "Solubilization of Matrix Protein M 1/M from Virions Occurs at Different pH for Orthomyxo-and Paramyxoviruses," <i>Virology</i> 176(1):274-279 (1990).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	